Tag Archive for: PrognostiX

Life Science Partner places entrepreneurial-minded sales exec to lead Cleveland Clinic’s diagnostic services spin-off

Life Science Partner announces the placement of Mark R.Willig, as CEO, at Cleveland-based PrognostiX, Inc. As the company’s chief executive, Willig will lead product development and commercialization of technology while overseeing finance and marketing strategy.

A medical diagnostics company founded by the Cleveland Clinic Foundation, PrognostiX’s testing kits and laboratory services focus on inflammatory processes in major disease areas including cardiovascular, respiratory, neurodegenerative disease and obesity.

“It’s been invigorating to watch this come together for the Cleveland Clinic Foundation’s first homegrown spin off,” says Thomas H. Callaway, Life Science Partner’s founder and president. “PrognostiX has won product approval, defined a strategy, and prepared for production. What they needed was an entrepreneur to catalyze sales and organizational development. Mark fits that bill very well.”

Willig joins another Life Science Partner placement at PrognostiX, Vijay Aggarwal, who is a member of the board of directors.

At both established and specialized diagnostic firms, as well as companies serving other healthcare fields, Willig has demonstrated his ability to devise successful go-to-market strategies while planning, assembling and managing effective sales forces. Previously with Specialty Labs, a clinical reference laboratory and diagnostic research company, he was senior vice president of sales and marketing. There, he set strategy for the sales and marketing organization, guiding transitions to a customer-driven focus, a vertical-markets approach, and greater international revenues. Under Willig, Specialty was the only national reference lab to record eight consecutive quarters of organic revenue growth.

As vice president of sales at Myriad Genetics, a biopharmaceutical company, Willig led an organization that saw sales increase by an average of 200 percent annually over a four-year period. Willig managed a total in-house staff of 106 people in addition to an alliance partner’s sales force of 700. He also held responsibility for sales infrastructure and process improvements including a customer relationship management software implementation.

With software developer Orca Medical Systems, as vice president of sales and marketing, Willig devised the start-up’s first marketing strategies, which targeted hospital emergency departments worldwide. He also recruited and trained a national sales force. Within 18 months, Orca won $3 million in new business and added some of the most prestigious provider organizations in the US to its client roster.

Willig began his career in the diagnostics division of Abbott Laboratories, a provider of diagnostic instrumentation and reagents to hospitals, clinics and reference labs. Most recently at Abbott, as integrated health systems manager, Willig had responsibility over a staff of 42 sales reps selling to and serving large healthcare systems.

Willig holds a bachelor’s degree from the University of Missouri.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits industry veteran to board of directors for emerging cardiovascular diagnostics firm

Life Science Partner announces the placement of Vijay Aggarwal, Ph.D., as a member of the board of directors for PrognostiX, Inc. Basing its work largely on research from The Cleveland Clinic, PrognostiX focuses on the role of inflammatory processes in cardiovascular, respiratory, and other disease areas.

“Early-stage companies like PrognostiX can really benefit from the advice and guidance of marketplace veterans,” says Thomas H. Callaway, Life Science Partner’s founder and president. “Vijay is an entrepreneurial CEO with an impressive history at market-leading clinical lab companies. He knows the diagnostic testing business, so we’re pleased that we were able to connect Vijay with PrognostiX’s board.”

Dr. Aggarwal is a seasoned executive who has held senior-level positions in the diagnostic lab sector as well as in pharmaceutical and medical device development. He agreed to join the board based on his assessment of PrognostiX’s core platform of laboratory tests, which show promise in enhancing cardiovascular diagnoses. He is currently CEO and president of Aureon Biosciences, which is developing pathology technologies that predict individual clinical outcomes by analyzing tissue.

Prior to Aureon, Dr. Aggarwal was president at aaiPharma. In addition to leading all research and development activities for this specialty pharmaceutical company, he was responsible for a $100 million contract product development business that served start-up, pharmaceutical, and medical device companies.

With Quest Diagnostics, as president of Quest Diagnostic Ventures, Dr. Aggarwal oversaw e-commerce strategy, pharmaceutical clinical trials, medical diagnostic equipment, medical informatics, point-of-care testing and other high-growth opportunities. He also held P&L responsibility for an existing product portfolio and headed the lab operations integration team during the merger between Quest and SmithKline Beecham Clinical Laboratories (SBCL).

With SBCL for more than a decade, Dr. Aggarwal rose from his position as a regional technical director to vice president and director of U.S. laboratories, with responsibility over $1.2 billion in sales.

Dr. Aggarwal has also consulted in the areas of e-prescribing, pharmacogenomics, healthcare informatics, clinical diagnostics and technology licensing for companies such as WebMD, Genomic Health, InstantDX, and Plexus Ventures.

Dr. Aggarwal holds a doctorate in pharmacology and toxicology from Virginia Commonwealth University, Medical College of Virginia Campus, and a bachelor’s degree in chemistry from Case Western Reserve University.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives: